The partner that turns portfolio into results
12 years of specialized pharma operations across Central America & the Caribbean.
High-value portfolio. Direct institutional access.
One regional operating partner.
Years in Operation
Active Countries
Units 2025
Institutional Channel
Your current portfolio has a ceiling
You the institutional market doesn't
Low-margin generics — Most local distributors compete in the same generics segment where margins shrink every year. Without biosimilars or specialty molecules, growth is structurally limited.
Institutional tenders out of reach — CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa represent 60%+ of the regional market. Winning tenders requires relationships, track record, and capacity that most distributors can’t access alone.
RTCA registrations: time and cost out of control — Registering in 6 countries requires specialized teams, 18–36 month timelines, and regulatory investment most distributors can’t carry without the manufacturer.
Access to high-value specialty molecules: biosimilars, biologics, anticoagulants, oncology, neurology, cardiovascular, and next-generation diabetes therapies. Portfolio without exclusivity conflicts.
Biosimilars and Biologics · Anticoagulants — leaders in hemophilia in Costa Rica · Oncology · Cardiovascular · Neurology and Antiepileptics · Second-Generation Diabetes
CTD dossiers for generics, biosimilars, and biologics under the RTCA framework. 83–100 point checklists per country. Active registrations maintained. We have never lost a file to a procedural error.
Specialized portfolio by therapeutic area
Anticoagulants and Hematology
Leaders in hemophilia treatment in Costa Rica. Portfolio with active registrations across all 6 countries. Direct institutional channel with CCSS, IGSS, and CSS.
Oncology and Biosimilars
Access to biosimilars from reference international manufacturers. Biological dossier management under RTCA. Experience in institutional oncology tenders.
Cardiovascular
Angiotensin inhibitors, calcium channel blockers, and antihypertensive agents. Active public and private channel across all 6 countries.
Diabetes and Metabolism
Second-generation hypoglycemic agents. Priority institutional access in chronic disease plans at CSS, CCSS, and IGSS.
Neurology
Antiepileptics with active registrations across the region. Experience in hospital-use protocols and chronic patient management.
High Specialty and Biologicals
Biologics from tier-1 international manufacturers. Cold chain management, special-use protocols, and patient follow-up. The fastest-growing segment in the region.
Results that speak for themselves.
Years in Operation
Active Countries
Units 2025
Institutional Channel
- 2021
Distributor of the Year (USA
- 2022
Largest CCSS Contract
- 2022
Happy Workers Award Panama
- 2023
Entrepreneur of the Year (USA)
- 2023
Leaders in Hemophilia — Costa Rica
Where we operate.
How we operate
Guatemala
IGSS · Instituto Guatemalteco de Seguridad Social
Fastest-growing market in our specialty portfolio.
Honduras
IHSS · Instituto Hondureño de Seguridad Social
Active institutional access. Specialized local sales force.
Dominican Republic
SeNaSa · Seguro Nacional de Salud
High-potential Caribbean market. Active institutional expansion.
El Salvador
ISSS · Instituto Salvadoreño del Seguro Social
Institutional and private pharmacy channel. Sustained growth.
Costa Rica
CCSS · Caja Costarricense de Seguro Social
Our largest contract to date. Leaders in Hemophilia treatment.
Panama
CSS · Caja de Seguro Social
Public and private institutional channel. Regional operational hub.
We are Lanco Medical Group
With 12 years of operations across Central America and the Caribbean, we’ve built what most distributors spend years trying to build: direct relationships with the region’s most important public health institutions, a team specialized by therapeutic area, and the regulatory infrastructure to register and maintain complex products.
We are not a generic distribution intermediary. We are the specialized operator that turns a high-value portfolio into institutional channel results. 144 million units consumed in 2025 are not a statistic — they are patients served.
Part of the LMG Bio Lifesciences ecosystem — the strategic platform connecting global pharma with Latin America.
- Which molecules in our portfolio are compatible with your current distribution network
- How joint institutional access works — tenders you can win with our backing
- What RTCA regulatory support is included at no extra cost
- Real margins — a structure designed for the distributor to win
No generic proposals. No commitments before understanding your operation.
I'm an international manufacturer
- Our active distribution network by country — contacts, sales history, institutions served
- Active RTCA registrations in our current portfolio — direct evidence of regulatory capacity
- Institutional tender track record — including the largest CCSS contract in our therapeutic area
- What the operational entry of your molecule would look like — timeline, responsibilities, regulatory investment
This isn't a pitch. It's a technical review of capabilities.
JUNTOS,
SÍ HACEMOS SALUD
Lanco Medical Group · info@lancomedicalgroup.com · www.lancomedicalgroup.com
Panamá · Costa Rica · Guatemala · Honduras · El Salvador · República Dominicana
© 2 0 2 6 L a n c o M e d i c a l G r o u p . To d o s l o s d e r e c h o s r e s e r v a d o s .
